CompletedPHASE2, PHASE3NCT05874037

Fluvoxamine for Long COVID-19

Studying Antisynthetase syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Washington University School of Medicine
Principal Investigator
Eric Lenze, MD
Washington University School of Medicine
Intervention
Fluvoxamine(drug)
Enrollment
191 enrolled
Eligibility
25 years · All sexes
Timeline
20232025

Study locations (1)

Collaborators

Balvi COVID Fund · BJH Townley Fund

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05874037 on ClinicalTrials.gov

Other trials for Antisynthetase syndrome

Additional recruiting or active studies for the same condition.

See all trials for Antisynthetase syndrome

← Back to all trials